Xencor | XNCR - الأصول





الأصول تغيير تاريخ
AbbVie USD 133.96B 62M 2025-12
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Arrowhead Research USD 1.6B 218.89M 2025-12
AstraZeneca USD 114.02B 59M 2026-03
Biogen USD 29.48B 43.6M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Cytokinetics USD 1.27B 151.06M 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
J&J USD 200.89B 1.68B 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
MacroGenics USD 256.85M 13.92M 2025-12
Merck USD 128.68B 8.18B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 207.62B 542M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Xencor USD 875.5M 6.68M 2025-12